Leading Gastrointestinal Cancer Experts Discuss Targeted Therapies and Landscape of Treatment

, ,

Tumor Board | <b>Tanios S. Bekaii-Saab, MD</b>

Tanios Bekaii-Saab, MD; Kristen Ciombor, MD, MSCI; and John Strickler, MD, detail key developments and needs in the gastrointestinal cancers landscape.

In a recent episode of Medical World News’ Second Opinion, Tanios Bekaii-Saab, MD, medical director of the Cancer Clinical Research Office and vice chair and section chief for Medical Oncology at the Mayo Clinic in Phoenix, Arizona, led a discussion with Kristen Ciombor, MD, MSCI, associate professor of medicine at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and John Strickler, MD, associate professor of medicine and co-leader of the Molecular Tumor Board at Duke University School of Medicine in Durham, North Carolina.

The conversation focused on articles published in the journal ONCOLOGY® looking at targeted therapies and the molecular treatment landscape for colorectal cancer. The medical oncologists detailed the COLOMATE and GOZILA platforms, tumor sequencing, and resistance to targeted therapies, among other topics.